New hope for kids with aggressive nerve cancer: immune-boosting combo trial opens
NCT ID NCT07375563
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests a powerful mix of chemotherapy, immunotherapy, and the child's own natural killer (NK) cells for children aged 1.5 to 18 with high-risk neuroblastoma that didn't respond or came back. The goal is to shrink tumors and improve survival by helping the immune system attack cancer more effectively. Only 5 participants will be enrolled at a single center in Russia.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GANGLIONEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National medical research center of pediatric haematology, oncology and immulogy named after Dmytriy Rogachyov, Moscow, 117198
RECRUITINGMoscow, 117198, Russia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Antibody-Chemo cocktail targets tough childhood cancer
- Engineered immune cells take aim at childhood cancer
- Engineered immune cells take aim at childhood cancer
- New hope for tough tumors: Half-Matched bone marrow transplant trial
- New combo therapy shows promise for tough childhood cancer
- Smart treatment strategy aims to spare kids with neuroblastoma from unnecessary side effects